FTC and New York AG miffed by overbiffing
By Lesley Fair
If you aren’t familiar with the word “overbiffing,” there’s no need to add it to your vocabulary. But if you know what overbiffing is and engage in it, a case just filed by the FTC and the New York Attorney General suggests now would be an excellent time to cut it out
.Read more >
The Federal Trade Commission is seeking comment on a proposed rule to implement a 2018 law requiring the nationwide consumer reporting agencies to provide free electronic credit monitoring services for active duty military consumers.
The Economic Growth, Regulatory Relief, and Consumer Protection Act, passed earlier this year, mandated that the FTC issue a rule regarding certain requirements of the law. The FTC’s Notice of Proposed Rulemaking (NPRM) proposes a rule that would require the nationwide consumer reporting agencies (CRAs) to provide a free electronic credit monitoring service that would notify active duty military members within 24 hours of any “material” additions or modifications to their credit files. It states that contact information, appropriate proof that the consumer is an active duty member of the military, and proof of the consumer’s identity may be required to take advantage of this service.
The proposed rule specifies how military consumers may prove their active duty status, such as providing a copy of their active duty orders. It also sets forth key terms such as “electronic credit monitoring service,” which is defined as a service through which the CRAs provide, at a minimum, electronic notification of material additions or modifications to a consumer’s file. In addition, the proposed rule prohibits the CRAs from requiring active duty military consumers to agree to terms or conditions, or representing that consumers must purchase a product or service in order to obtain the free credit monitoring service. The NPRM seeks comment on these provisions and other aspects of the proposed rule such as:
The Commission vote to approve publishing the NPRM in the Federal Register was 5-0.
The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about consumer topics and file a consumer complaint online or by calling 1-877-FTC-HELP (382-4357). Like the FTC on Facebook, follow us on Twitter
MedWatch - The FDA Safety Information and Adverse Event Reporting Program
A new MedWatch Safety Alert: FDA Warns Against the Use of Many Genetic Tests with Unapproved Claims to Predict Patient Response to Specific Medications: FDA Safety Communication intended for: Patient, Consumer, Health Professional was just added to the FDA Medical Device Safety, Safety Communications Webpage.
You can read the complete FDA Safety Communication that includes recommendations at: https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm624725.htm
A new MedWatch Safety Alert: Device Failure Associated with Getinge's Maquet/Datascope Intra-Aortic Balloon Pumps - Letter to Health Care Providers intended for:
Cardiology, Anesthesiology, Critical Care Medicine, Nursing, Biomedical Engineering was just added to the FDA Medical Device Safety, Letters to Health Care Providers Webpage.
You can read the complete Letter to Health Care Providers that includes recommendations at: https://www.fda.gov/MedicalDevices/Safety/LetterstoHealthCareProviders/ucm624734.htm
A new MedWatch Safety Alert recall: Irbesartan Drug Substance by Aurobindo Pharma Limited: Recall - Due to the Detection of Trace Amounts of NDEA (NNitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient was just added to the FDA Recalls webpage.
You can read the complete recall alert at: https://www.fda.gov/Safety/Recalls/ucm624547.htm
Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP 75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API) ScieGen Pharmaceuticals, Inc. is voluntarily recalling listed lots, within expiry, of Irbesartan Tablets, USP 75 mg, 150 mg, and 300 mg dosage forms to the consumer level. These products are being recalled due to the presence of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Irbesartan, USP manufactured by Aurobindo Pharma Limited. This impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) To date, Sciegen Pharmaceuticals Inc has not received any reports of adverse events related to this product. Irbesartan tablets, USP are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. Maribel’s Sweets Inc. of Brooklyn, NY is recalling its 2.82oz MarieBelle Japanese Matcha Japanese Green Tea and White Chocolate Bar, container code 101619, Cacao Market by MarieBelle Rosemary Truffle Salt 60% Dark Chocolate Bar, all container codes, and the Cacao Market by MarieBelle Orange Peels 60% Dark Chocolate Bar, all container codes, because they may contain undeclared milk allergens. Consumers who are allergic to milk allergens may run the risk of serious or life-threatening allergic reactions if they consume this product. The recalled 2.82oz MarieBelle Japanese Matcha Japanese Green Tea and White Chocolate Bar, container code 101619, Cacao Market by MarieBelle Rosemary Truffle Salt 60% Dark Chocolate Bar, all container codes, and the Cacao Market by MarieBelle Orange Peels 60% Dark Chocolate Bar, all container codes have the UPC codes 877708005886 (Cacao Market Japanese Matcha Bar) 877708004803 (Cacao Market Orange Peel Bar) and 877708004841 (Rosemary Truffle Salt Bar). |